BEATBEATHealthcare · Health Information Services

BEAT Stock Forecast: HeartBeam, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$0.49
+3.14% on the day

The 4 Wall Street analysts covering HeartBeam, Inc. hold a median 12-month price target of $3.25 — +558.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 18 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$27.8M
Ticker Nerd rank
18 / 100
Median analyst target
$3.25
Analysts covering
4
Total return, dividends reinvested
1W
−1.1%
1M
−16.7%
YTD
−79.4%
1Y
−54.3%
From 52W high
−85.7%
From 52W low
+3.1%
$0.48
$3.44
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BEAT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores HeartBeam, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
18 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
87
Growth
74
Volatility
53
Accruals
45
Revisions
35
Issuance
31
Momentum
7
Value
5
Quality
2

Size (87): Smaller than most of the companies we track.

Quality (2): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BEAT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BEAT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00$5.00Oct 25Jan 26Apr 26Jul 26BEATHigh $5.00Median $3.25Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $2.00Median $3.25High $5.00

The green dot is the last close — the median target sits +558.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 July 2026Maxim GroupInitiatesBuy$2.00
22 May 2026HC Wainwright & Co.MaintainsBuy$5.50$2.50
22 May 2026HC Wainwright & Co.MaintainsBuy
15 May 2026BenchmarkMaintainsSpeculative Buy$8.00$5.00
15 May 2026BenchmarkMaintainsSpeculative Buy
31 Mar 2026B. Riley SecuritiesInitiatesBuy
30 Mar 2026D. Boral CapitalMaintainsBuy
27 Mar 2026D. Boral CapitalInitiatesBuy
16 Mar 2026HC Wainwright & Co.ReiteratesBuy
11 Dec 2025BenchmarkUpgradeBuy
10 Dec 2025HC Wainwright & Co.MaintainsBuy
8 Dec 2025HC Wainwright & Co.InitiatesBuy
15 Nov 2024BenchmarkReiteratesSpeculative Buy
4 Sept 2024BenchmarkReiteratesSpeculative Buy$8.00
13 May 2024BenchmarkReiteratesSpeculative Buy
25 Mar 2024BenchmarkReiteratesSpeculative Buy
16 Nov 2023BenchmarkReiteratesSpeculative Buy
24 Aug 2023BenchmarkReiteratesSpeculative Buy
19 May 2023Alliance Global PartnersMaintainsBuy
19 May 2023BenchmarkReiteratesSpeculative Buy

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BEAT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

BEAT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
0
Fundamentals

HeartBeam, Inc. (BEAT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.8×

Cheaper than 81% of US stocks

Price / sales
Price / book
32.9×

Cheaper than 3% of US stocks

EV / EBITDA
−0.9×

Cheaper than 66% of US stocks

Growth & margins
Revenue growth (YoY)
Earnings growth (YoY)
Gross margin
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−328.4%

Higher than 5% of US stocks

Return on assets
−153.5%

Higher than 1% of US stocks

Dividend yield

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

BEAT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services
CompanyMarket capTKN rank
BEATHeartBeam, Inc.$27.8M
18
ONMDOneMedNet Corp.$35.6M
17
HCTIHealthcare Triangle, Inc.$13.2M
22
BFRGBullFrog AI Holdings, Inc.$10.8M
37
DRIODarioHealth Corp.$73.4M
44
MGRXMangoceuticals, Inc.$9.1M
44
ACONAclarion, Inc.$7.8M
33

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own HeartBeam, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BEAT news & analysis

HeartBeam, Inc. (BEAT) Q2 2026 Earnings Call Transcript

Seeking Alpha · 14 Aug 2026neutral

HeartBeam, Inc. (BEAT) published the transcript of its Q2 2026 earnings call on Seeking Alpha. The transcript covers the company's quarterly earnings discussion.

Why it matters — BEAT watchers would turn to the transcript for management's commentary on the company's second-quarter results and outlook.

HeartBeam Reports Second Quarter 2026 Results

Business Wire · 13 Aug 2026neutral

HeartBeam, Inc. announced its financial results for the second quarter of 2026 via a Business Wire release dated from Santa Clara, California.

Why it matters — Earnings reports provide insight into the company's recent financial performance, which is key information for those following HeartBeam.

FAQ

Frequently asked questions about BEAT stock

What is the BEAT stock price forecast for 2026-2027?

The 4 Wall Street analysts covering HeartBeam, Inc. have a median 12-month price target of $3.25, with estimates ranging from $2 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BEAT stock a buy right now?

Of the 4 analysts covering HeartBeam, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks HeartBeam, Inc. 18 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BEAT?

As at 22 Aug 2026, HeartBeam, Inc. ranks 18 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (87 of 100).

Will BEAT stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +558.8% from the last close, and Ticker Nerd's factor model ranks HeartBeam, Inc. 18 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BEAT stock forecast for 2030?

No analyst covering HeartBeam, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BEAT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $5 over the next 12 months.

How has BEAT stock performed over the past year?

HeartBeam, Inc. returned -54.3% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does HeartBeam, Inc. do?

HeartBeam Inc. is a medical technology company focused on transforming cardiac disease detection and monitoring through innovative electrocardiogram solutions.

What is the latest news on BEAT?

The most recent item we track (Seeking Alpha, 14 Aug 2026): "HeartBeam, Inc. (BEAT) Q2 2026 Earnings Call Transcript". HeartBeam, Inc. (BEAT) published the transcript of its Q2 2026 earnings call on Seeking Alpha. The transcript covers the company's quarterly earnings discussion.

Company

About HeartBeam, Inc.

HeartBeam Inc. is a medical technology company focused on transforming cardiac disease detection and monitoring through innovative electrocardiogram solutions. The company has developed the first cable-free device capable of collecting electrocardiogram signals in three dimensions from non-coplanar directions and synthesizing them into clinical-grade 12-lead electrocardiograms. HeartBeam's flagship product, HeartBeam AIMIGo, is a credit card-sized portable device coupled with a smartphone application and cloud-based diagnostic software system that enables remote evaluation of cardiac symptoms outside traditional healthcare settings. The company's proprietary Vector Electrocardiography platform creates three-dimensional vector images of cardiac electrical activity, allowing physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care. HeartBeam received FDA clearance for its 3D electrocardiogram technology for arrhythmia assessment in December 2024 and for its 12-lead electrocardiogram synthesis software in December 2025. The platform is designed for use in both clinical and at-home settings, with readings reviewed by on-demand board-certified cardiologists. Founded in 2015 and headquartered in Santa Clara, California, HeartBeam holds over 20 issued patents related to its technology and is advancing applications in heart attack detection and artificial intelligence-enabled cardiac screening.

CEO Mr. Robert P. Eno · 16 employees · United States · https://www.heartbeam.com